Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


MHLW Approves Erbitax, Thymoglobulin And Mycobutin

This article was originally published in PharmAsia News

Executive Summary

The Second Division of the Pharmaceutical and Food Sanitation Council of the Ministry of Health, Labor and Welfare approved three drugs May 23: Merck's Erbitax (cetuximab), Sanofi-Aventis' Thymoglobulin IV infusion and Pfizer's Mycobutin (rifabutin). Cetuximab is the second approved molecular-targeted colon and rectum cancer drug after Chugai's Avastin (bevacizumab). Thymoglobulin is applied to treat moderate to severe aplastic anemia. Mycobutin is used to treat tuberculosis and prevent disseminated mycobacterium avium complex, a disease in patients with advanced HIV infection. After the division reports the items to the Pharmaceutical Affairs section meeting in June, formal approvals are estimated to be in middle July. (Click here for more - Japanese language

You may also be interested in...

Ready, Set, Guidance: FDA Releases Final Details Ahead Of ASCA Pilot Launch

A trio of newly finalized guidance documents from the US agency dated 25 September explain how the Accreditation Scheme for Conformity Assessment pilot will work, and what biocompatibility and safety standards will apply.

With Preservative-Free Alaway Eye Drops, Bausch Expands OTC Portfolio Of Planned Spin-Off

Approval of Alaway Preservative Free (ketotifen fumarate, 0.035) comes 15 months after FDA submitted a complete response letter to Bausch and the active ingredient developer, Eton Pharmaceuticals. 

In US, Market Exclusivity For NDI Notifications ‘Just Not There’ In DSHEA Regulation

Unfounded expectation some firms have for FDA to protect their investments in preparing successful NDI notifications is part of industry’s overall interest in increased regulation of the market, says Steven Tave, Office of Dietary Supplement Programs director.




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts